FMP
Madrigal Pharmaceuticals, Inc.
MDGL
NASDAQ
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
312.77 USD
-5.67 (-1.81%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Mr. William J. Sibold
sector
Healthcare
industry
Biotechnology
exchange
NASDAQ
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
CIK
0001157601
ISIN
US5588681057
CUSIP
558868105
Address
Four Tower Bridge
Phone
267 824 2827
Country
US
Employee
376
IPO Date
Feb 6, 2007
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
MDGL Financial Summary
CIK
0001157601
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
558868105
ISIN
US5588681057
Country
US
Price
312.77
Beta
-0.47
Volume Avg.
408.23k
Market Cap
6.82B
Shares
-
52-Week
168.25-368.29
DCF
-0.92
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-12.5
P/B
-
Website
https://www.madrigalpharma.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest MDGL News
It looks like there's no news available.
